For a research institution to achieve its potential, its executive team must cultivate a spirit of inspiration and support. While Profil has grown quickly in recent years, we are proud of the stability and approachability of our management. Our executive team are involved in our day-to-day research into diabetes and obesity, remaining in direct contact with their teams of medical, scientific and informatics experts. Since their goal has always been scientific excellence rather than rapid growth, they also inspire their teams to strive for excellence in all Profil does.
Read about the entrepreneurial scientists who lead Profil.
Download our recent conference posters for free.
Chief Executive Officer
Prof. Dr. Leona Plum-Mörschel has over 15 years of experience in basic research, translational clinical research and early-phase clinical development in the field of obesity, diabetes, and metabolism. She joined Profil in 2010.
Chief Commercial Officer
Lars has an academic background and a Ph.D. in molecular medicine / molecular biology. He joined Profil in 2015 and he is active in strategic organizational development and responsible for Profil's commercial operations, study volunteer recruitment and general study inquiries.
Executive Director Finance
Denise has more than 15 years of experience in finance. Before joining Profil in 2020, she worked in tax consultancy and in a senior finance role in the food industry.
Executive Director Human Resources
Martin has more than 30 years of experience in Human Resources Management. Before joining Profil in 2015, he worked in the Pharmaceutical Industry and as Managing Partner in the Field of Executive Search.
Executive Project Director
Eric is a clinical research specialist and is well-known for his scientific contributions to international meetings and diabetes journals. His main expertise lies in the field of diabetes technology and alternative route administrations of insulin.
We have published with the following sponsors:
 ISO 13485:2016
|
 ISO 9001:2015
|
Kapitza, C. et al. 2021. A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes. Diabetes Obes Metab. 2021 Mar;23(3):674-681
